Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | PTGER1 | P34995 | 13/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | DHODH | Q02127 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPY1R | P25929 | 1/20 | 0.39 |
| ▸ | NPY2R | P49146 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4154616 | 0.94 | PTGER1 (0.47) | MRGPRX4PTGER1CYP2C9 | |
| SCHEMBL4162796 | 0.89 | PTGER1 (0.44) | MRGPRX4PTGER1CYP2C9 | |
| SCHEMBL4166655 | 0.87 | PTGER1 (0.48) | MRGPRX4PTGER1CYP2C9ALKBH1 | |
| SCHEMBL4162433 | 0.87 | PTGER1 (0.44) | MRGPRX4PTGER1CYP2C9 | |
| SCHEMBL4163102 | 0.87 | PTGER1 (0.53) | MRGPRX4PTGER1CYP2C9 | |
| SCHEMBL13697257 | 0.86 | PTGER1 (0.48) | MRGPRX4PTGER1CYP2C9 | |
| SCHEMBL4155598 | 0.85 | PTGER1 (0.48) | MRGPRX4PTGER1CYP2C9 | |
| SCHEMBL4149578 | 0.85 | PTGER1 (0.44) | MRGPRX4PTGER1CYP2C9 | |
| SCHEMBL13697214 | 0.85 | PTGER1 (0.59) | MRGPRX4PTGER1CYP2C9 | |
| SCHEMBL4147446 | 0.85 | PTGER1 (0.44) | MRGPRX4PTGER1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227591-A1 | Cyclopentene compounds | C1R, CYP1B1, ADORA2B | MRGPRX4 435/4885PTGER1 246/4885CYP2C9 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.